Oryzon Genomics S.A.
ORYZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7,359 | $14,192 | $15,698 | $10,615 |
| % Growth | -48.1% | -9.6% | 47.9% | – |
| Cost of Goods Sold | $302 | $244 | $464 | $746 |
| Gross Profit | $7,057 | $13,948 | $15,234 | $9,869 |
| % Margin | 95.9% | 98.3% | 97% | 93% |
| R&D Expenses | $5,926 | $6,236 | $6,630 | $7,354 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,638 | $3,606 | $3,569 | $3,671 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,915 | $8,655 | $10,525 | $5,855 |
| Operating Expenses | $11,480 | $18,497 | $20,724 | $16,880 |
| Operating Income | -$4,423 | -$4,549 | -$5,490 | -$7,011 |
| % Margin | -60.1% | -32.1% | -35% | -66% |
| Other Income/Exp. Net | -$1,148 | -$1,555 | -$1,067 | -$169 |
| Pre-Tax Income | -$5,571 | -$6,104 | -$6,557 | -$7,180 |
| Tax Expense | -$1,906 | -$2,751 | -$2,325 | -$2,493 |
| Net Income | -$3,665 | -$3,353 | -$4,231 | -$4,687 |
| % Margin | -49.8% | -23.6% | -27% | -44.2% |
| EPS | -0.057 | -0.055 | -0.076 | -0.089 |
| % Growth | -2.7% | 27% | 15% | – |
| EPS Diluted | -0.057 | -0.055 | -0.076 | -0.089 |
| Weighted Avg Shares Out | 64,747 | 60,879 | 56,042 | 52,762 |
| Weighted Avg Shares Out Dil | 64,747 | 60,879 | 56,042 | 52,762 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $34 | $12 | $6 |
| Interest Expense | $1,111 | $1,894 | $1,119 | $456 |
| Depreciation & Amortization | $126 | $130 | $147 | $133 |
| EBITDA | -$4,376 | -$4,433 | -$5,350 | -$6,880 |
| % Margin | -59.5% | -31.2% | -34.1% | -64.8% |